Birchview Capital’s Cogent Biosciences COGT Stock Holding History

Birchview Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$287K	–	74
2025 Q2	$287K	Buy	+40,000	New	+$222K	0.29%	53

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Birchview Capital's COGT Position: Q3 2025 in Review

Birchview Capital sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 40,000 shares — an estimated $287K sold.

Birchview Capital first reported a position in COGT in Q2 2025 and held it in 1 quarter. The position peaked at $287K in Q2 2025. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

Birchview Capital reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
Birchview Capital sold 40,000 Cogent Biosciences shares in Q3 2025, an estimated $287K.
Birchview Capital first reported a position in Cogent Biosciences in Q2 2025 and held it in 1 quarter.
Birchview Capital's Cogent Biosciences position peaked at $287K in Q2 2025.
195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.